http://www.pharmexeceurope.com/europharmexec Latest content from Pharmaceutical Executive Europe, the leading strategy-based, business management portal and e-zine for senior executives, corporate strategists and sales & marketing leaders in the European pharmaceutical industry. 2008-09-05T17:48:29Z http://www.pharmexeceurope.com/europharmexec/An-Alternative-Drug-Development-Model/ArticleStandard/Article/detail/547850?ref=25 Ian Massey, CEO of Synosia Therapeutics, offers a personal perspective on how a lean but efficient drug development model can pay dividends for smaller pharma companies. 2008-09-05T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/362008/547850null HTML http://www.pharmexeceurope.com/europharmexec/Turn-Your-Strategic-Weaknesses-into-Strengths/ArticleStandard/Article/detail/547851?ref=25 Does your firm meet the much-vaunted VRIO (valuable, rare, imitable and organisationally aligned) criteria? Dr Brian D. Smith looks at how you can sharpen these competencies and see real results. 2008-09-05T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/362008/547851null HTML http://www.pharmexeceurope.com/europharmexec/Reflector/EMEA-Gets-tough-on-meetings/ArticleStandard/Article/detail/546838?ref=25 Reflector outlines what you can expect if you have a meeting with EMEA lined up in the near future. 2008-09-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/362008/546838null HTML http://www.pharmexeceurope.com/europharmexec/New-Format-for-Pharm-Exec-Europe/ArticleStandard/Article/detail/546837?ref=25 Check out the new easier-to-open, easier-to-navigate and easier-to-read digital magazine here. 2008-09-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/362008/546837null HTML http://www.pharmexeceurope.com/europharmexec/Celsis-Rapid-Detection-System/ArticleStandard/Article/detail/546836?ref=25 If your company is trying to get leaner, take a look at your microbial testing method. Celsis Rapid Detection systems offer results 80% faster than traditional methods — in hours instead of days or weeks. Results are equivalent or better than traditional methods and accepted by regulatory agencies worldwide. Celsis systems are used to screen the widest range of range of pharmaceutical products of any rapid method. 2008-09-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/362008/546836null HTML http://www.pharmexeceurope.com/europharmexec/AZ-goes-east-for-anticancer-collaboration/ArticleStandard/Article/detail/546839?ref=25 AstraZeneca's director of Discovery Medicine, Clinical Oncology, Andrew Hughes, talks to Bibi Campos Seijo about the company's recently-signed collaboration agreement with Singapore. 2008-08-29T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/362008/546839null HTML http://www.pharmexeceurope.com/europharmexec/News/18-Aug-08-Pfizer-announces-closure-of-Irish-manufa/ArticleStandard/Article/detail/542722?ref=25 Pfizer has announced that it is going to close its manufacturing site in Cork, resulting in the loss of 180 jobs. 2008-08-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/342008/542722null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/How-employee-misunderstanding-costs-pharma-50-mill/ArticleStandard/Article/detail/542193?ref=25 Mary Clarke, CEO of Cognisco, outlines the shocking implications that the varying degrees of 'employee misunderstanding' can have for the pharma industry. 2008-08-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/332008/542193/US_Money_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Sales+%26+Marketing/Do-you-know-your-eMarket/ArticleStandard/Article/detail/542203?ref=25 Carol Blenkin examines some of the ways in which pharma marketers can deploy eMarketing, online advertising and Web 2.0 technologies to target niche markets or a specific audience. 2008-08-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/332008/542203null HTML http://www.pharmexeceurope.com/europharmexec/News/18-Aug-08-Pfizer-buys-rights-to-Immunodrug-technol/ArticleStandard/Article/detail/542724?ref=25 Pfizer is to pay $137 million for the use of Cytos Biotechnology's Immunodrug technology. 2008-08-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/342008/542724null HTML http://www.pharmexeceurope.com/europharmexec/News/18-Aug-08-Abbott-to-promote-Crestor-in-the-US/ArticleStandard/Article/detail/542723?ref=25 Abbott has struck a deal with AstraZeneca to promote the cholesterol-lowering drug Crestor (rosuvastatin calcium) in the US. 2008-08-18T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/342008/542723null HTML http://www.pharmexeceurope.com/europharmexec/News/14-Aug-08-Genentech-reject-Roches-offer/ArticleStandard/Article/detail/542191?ref=25 Genentech has turned down a buyout offer from its majority owner, Roche. 2008-08-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/332008/542191null HTML http://www.pharmexeceurope.com/europharmexec/News/11-Aug-08-Bayer-in-generic-fight-with-Sandoz/ArticleStandard/Article/detail/534958?ref=25 Bayer has filed a patent infringement lawsuit against Sandoz, the generic medication division of Novartis, related to the oral contraceptive YAZ. 2008-08-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/332008/534958null HTML http://www.pharmexeceurope.com/europharmexec/CURRENT-ISSUE/ArticleStandard/Article/detail/480000?ref=25 View the latest issue of Pharmaceutical Executive Europe for FREE now. 2008-08-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/512007/480000null HTML http://www.pharmexeceurope.com/europharmexec/Featured+articles/IT-and-the-IMI/ArticleStandard/Article/detail/544731?ref=25 How can IT impact the EU's Innovative Medicines Initiative? Pharm Exec Europe's IT guru George Laszlo investigates. 2008-08-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/352008/544731/EUFlag_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/IMI-SRA-151-KEY-POINTS/ArticleStandard/Article/detail/544837?ref=25 Key points 2008-08-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/352008/544837null PDF http://www.pharmexeceurope.com/europharmexec/Featured+articles/Steering-Pharma-in-Russia/ArticleStandard/Article/detail/544838?ref=25 Click here for the first of Gerhard Symons' three reports on pharma developments in the Russian Federation. 2008-08-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/352008/544838/RussianFlag_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/IT-and-the-IMI-Table-1/ArticleStandard/Article/detail/544833?ref=25 Table 1 2008-08-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/352008/544833null PDF http://www.pharmexeceurope.com/europharmexec/The-EUs-autumn-regulatory-line-up-a-preview/ArticleStandard/Article/detail/532667?ref=25 Summer may already be well under way, but Reflector sees things hotting up further when the EU reconvenes in the autumn. 2008-07-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/312008/532667null HTML http://www.pharmexeceurope.com/europharmexec/How-useful-is-management-theory/ArticleStandard/Article/detail/532670?ref=25 It depends on your grasp of its foundations, argues Dr Brian D. Smith. 2008-07-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/312008/532670null HTML http://www.pharmexeceurope.com/europharmexec/Event-profile-BIO-Europe-2008-151-Global-Biotech-P/ArticleStandard/Article/detail/532673?ref=25 The 14th annual BIO-Europe event is the world?s largest dedicated biotechnology partnering conference. Over 2,200 global decision-makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. 2008-07-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/312008/532673null HTML http://www.pharmexeceurope.com/europharmexec/News/30-July-08-Synosia-Initiates-Drug-Therapy-Study-fo/ArticleStandard/Article/detail/532672?ref=25 Phase IIa trial of nepicastat (SYN-117) starts enrolment 2008-07-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/312008/532672null HTML http://www.pharmexeceurope.com/europharmexec/What-is-predictive-design/ArticleStandard/Article/detail/532888?ref=25 Mick Withers provides an explanation of predictive design and outlines how it can help you get your product to market faster. 2008-07-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/312008/532888null HTML http://www.pharmexeceurope.com/europharmexec/News/21-July-08-Sanofi-offer-snubbed-by-Zentiva/ArticleStandard/Article/detail/530852?ref=25 The board of Czech generic drugs maker Zentiva, has recommended that its shareholders reject a takeover offer from Sanofi-Aventis. 2008-07-21T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/302008/530852null HTML http://www.pharmexeceurope.com/europharmexec/News/21-July-08-Roche-makes-Genentech-an-offer/ArticleStandard/Article/detail/530893?ref=25 Roche has offered to buy all outstanding shares in its US partner Genentech for $43.7 billion. 2008-07-21T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/302008/530893null HTML http://www.pharmexeceurope.com/europharmexec/News/21-July-08-Teva-to-buy-Barr/ArticleStandard/Article/detail/530851?ref=25 Teva Pharmaceutical is to buy the rival generic drug company, Barr Pharmaceuticals, for more than $7 billion. 2008-07-21T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/302008/530851null HTML http://www.pharmexeceurope.com/europharmexec/News/17-July-08-Phenomenex-moves-into-The-Netherlands/ArticleStandard/Article/detail/530305?ref=25 Phenomenex, manufacturer of separation science consumables, has opened a new subsidiary in Utrecht, The Netherlands. 2008-07-17T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/530305null HTML http://www.pharmexeceurope.com/europharmexec/News/17-July-08-Nycomed-and-Immunomedics-agree-veltuzum/ArticleStandard/Article/detail/530304?ref=25 Nycomed and Immunomedics have announced a collaboration and licensing agreement on Immunomedics' veltuzumab. 2008-07-17T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/530304null HTML http://www.pharmexeceurope.com/europharmexec/News/16-July-08-Ranbaxy-denies-accusations-of-fraud/ArticleStandard/Article/detail/529990?ref=25 A motion filed by the US Department of Justice is seeking certain documents from the Indian drugmaker, Ranbaxy, as part of an investigation into whether it falsified data on treatments. 2008-07-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/529990null HTML http://www.pharmexeceurope.com/europharmexec/Reflector/Trust-us-were-the-pharma-industry/ArticleStandard/Article/detail/529981?ref=25 Reflector reviews the EFPIA's new code of practice for dealing with patient organisations. 2008-07-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/529981null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/Put-your-company-on-the-Best-Place-to-Work-list/ArticleStandard/Article/detail/529984?ref=25 Novo Nordisk was recently ranked among the top 10 UK's best work places in a poll conducted by the Great Place to Work Institute. Phil Morley, creative director at communications agency, blue goose, looks at some general rules for improving communication effectiveness. 2008-07-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/529984null HTML http://www.pharmexeceurope.com/europharmexec/Interviews+and+comment%3A+Corporate+Strategy/Is-buy-in-really-worth-it/ArticleStandard/Article/detail/529982?ref=25 Dr Brian D. Smith looks at the value of management science to real-world pharmaceutical executives. 2008-07-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/529982null HTML http://www.pharmexeceurope.com/europharmexec/News/16-July-08-Roche-UK-suspended-from-the-APBI/ArticleStandard/Article/detail/529989?ref=25 The UK unit of Roche has had its membership of the Association of the British Pharmaceutical Industry suspended for at least six months in connection with serious breaches of the APBI Code of Practice between 2003 and 2005. 2008-07-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/529989null HTML http://www.pharmexeceurope.com/europharmexec/News/15-JUL-08-Novo-Nordisk-seeks-Japanese-approval-for/ArticleStandard/Article/detail/529804?ref=25 Novo Nordisk announce submission of a new drug application. 2008-07-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/292008/529804null HTML http://www.pharmexeceurope.com/europharmexec/News/08-JUL-08-GSK-says-no-to-generics/ArticleStandard/Article/detail/528532?ref=25 Andrew Witty declares 'no interest' in generics market place 2008-07-07T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/282008/528532null HTML http://www.pharmexeceurope.com/europharmexec/The-EU-Raids-on-Pharma-EFPIA-Predicts-Verdict/ArticleStandard/Article/detail/526698?ref=25 A new European Federation of Industries and Associations report expresses industry fears after Neelie Kroes's January raids. 2008-07-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/272008/526698null HTML http://www.pharmexeceurope.com/europharmexec/News/Grow-Your-Oncology-Brand/ArticleStandard/Article/detail/526971?ref=25 Join IMS's Educational Oncology Market Webinars, 8–17 July. 2008-07-01T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/272008/526971null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/How-to-Partner-with-AstraZeneca/ArticleStandard/Article/detail/526758?ref=25 At the BIO convention earlier this month, Pharm Exec Europe caught up with AZ's Global Discovery Research, Dr Jan Lundberg, for his take on how to catch a pharma giant's eye. 2008-06-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/272008/526758/lundbergflash_flash.jpg HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/How-To-Partner-with-Roche/ArticleStandard/Article/detail/526727?ref=25 Warwick S. Bedwell, Roche's Global Head of Business Development talks to Pharm Exec Europe about what he looks for in a good biotech partner. 2008-06-30T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/272008/526727/BedwellFlash2_flash.JPG HTML http://www.pharmexeceurope.com/europharmexec/News/27-June-08-New-vaccination-production-plant-opens-/ArticleStandard/Article/detail/526442?ref=25 Sanofi Pasteur has opened a new €100 million vaccination production plant in Val de Reuil, France. 2008-06-27T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/262008/526442null HTML http://www.pharmexeceurope.com/europharmexec/News/25-June-08-Bayer-signs-agreement-with-US-generic-c/ArticleStandard/Article/detail/525918?ref=25 Bayer AG has signed a supply and licensing agreement with the American generic drug manufacturer Barr Pharmaceuticals. 2008-06-25T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/262008/525918null HTML http://www.pharmexeceurope.com/europharmexec/News/20-June-2008-Pfizer-and-Ranbaxy-reach-an-agreement/ArticleStandard/Article/detail/525105?ref=25 A settlement between Pfizer and Ranbaxy means that the latter will be able to start selling its generic form of the cholesterol drug Lipitor by late 2011. 2008-06-20T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/252008/525105null HTML http://www.pharmexeceurope.com/europharmexec/News/19-June-08-ThromboGenics-and-BioInvent-strike-a-de/ArticleStandard/Article/detail/524905?ref=25 ThromboGenics and BioInvent International have entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. 2008-06-19T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/252008/524905null HTML http://www.pharmexeceurope.com/europharmexec/News/17-June-08-Aflunov-application-withdrawn-by-Novart/ArticleStandard/Article/detail/524359?ref=25 Novartis Vaccines and Diagnostics has withdrawn its marketing application with the European Medicines Agency (EMEA) for the Aflunov H5N1 vaccine. 2008-06-17T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/252008/524359null HTML http://www.pharmexeceurope.com/europharmexec/News/16-June-08-Rumours-that-Pfizer-may-make-counter-bi/ArticleStandard/Article/detail/524133?ref=25 Pfizer may make a counter bid for Ranbaxy, following Daiichi Sankyo's bid of $4.6 billion. 2008-06-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/252008/524133null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/Glaxo-to-emulate-small-biotech-business-model/ArticleStandard/Article/detail/523707?ref=25 Pharma giant to form smaller units to resharpen its focus. 2008-06-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/523707null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/Daiichi-Sankyo-makes-move-on-Ranbaxy/ArticleStandard/Article/detail/523699?ref=25 More evidence that Japan is embracing generics. 2008-06-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/523699null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/Dont-Let-EDC-Disrupt-Your-Flow/ArticleStandard/Article/detail/523697?ref=25 George Laszlo advocates consideration when implementing an electronic publishing system. 2008-06-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/523697null HTML http://www.pharmexeceurope.com/europharmexec/Reflector/Three-Steps-to-Patient-Information-Heaven/ArticleStandard/Article/detail/523698?ref=25 The EU is gearing up to address the topic of patient communication. But we'd better not hold our collective breath, says Reflector. 2008-06-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/523698null HTML http://www.pharmexeceurope.com/europharmexec/Featured+articles/New-Survey/ArticleStandard/Article/detail/512920?ref=25 How far behind the US would you say is the European biotech industry? Tell us what you think. 2008-06-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/512920/vote2_flash.jpg REMOTE http://www.pharmexeceurope.com/europharmexec/News/11-June-08-NovoSeven-trial-abandoned/ArticleStandard/Article/detail/523345?ref=25 Novo Nordisk has announced that it is to discontinue its Phase III clinical trial of NovoSeven. 2008-06-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/523345null HTML http://www.pharmexeceurope.com/europharmexec/News/11-June-08-GSK-wields-the-axe/ArticleStandard/Article/detail/523383?ref=25 GlaxoSmithKline (GSK) is planning to axe 350 jobs in its R&D operations. 2008-06-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/523383null HTML http://www.pharmexeceurope.com/europharmexec/News/11-June-08-Symphogen-amp-Genentech-make-a-deal/ArticleStandard/Article/detail/523384?ref=25 Symphogen has made a $330 million deal with Genentech to discover new antibodies for three infectious disease targets. 2008-06-11T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/523384null HTML http://www.pharmexeceurope.com/europharmexec/News/10-June-08-Faking-it-151-60-of-meds-bought-online-/ArticleStandard/Article/detail/522727?ref=25 A report by the European Alliance for Access to Safe Medicines (EAASM) has revealed that 60% of medicines sold by online pharmacies are fake or substandard. 2008-06-10T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/522727null HTML http://www.pharmexeceurope.com/europharmexec/News/10-June-08-Astex-signs-drug-deal-with-Johnson-amp-/ArticleStandard/Article/detail/522730?ref=25 Astex Therapeutics, the privately owned British biotech company, has signed a cancer drug research deal with Johnson & Johnson. 2008-06-10T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/522730null HTML http://www.pharmexeceurope.com/europharmexec/PEE-2008-Readership-survey/ArticleStandard/Article/detail/522440?ref=25 PEE 2008 Readership survey 2008-06-09T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/242008/522440null HTML http://www.pharmexeceurope.com/europharmexec/News/05-June-08-Novartis-all-set-to-buy-Protez/ArticleStandard/Article/detail/521797?ref=25 Novartis is to acquire Protez Pharmaceuticals, a company founded by BTG plc. 2008-06-05T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/232008/521797null HTML http://www.pharmexeceurope.com/europharmexec/News/04-JUN-08-Molecular-Profiles-to-add-to-its-trophy-/ArticleStandard/Article/detail/521287?ref=25 CEO Dr Nikin Patel nominated for healthcare award 2008-06-04T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/232008/521287null HTML http://www.pharmexeceurope.com/europharmexec/Reflector/Direct-to-consumer-advertising-results-from-the-la/ArticleStandard/Article/detail/520557?ref=25 Reflector ponders whether the new EC report on DTC is a useful policy making or just another exercise in stating "the bleeding obvious." 2008-06-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/232008/520557null HTML http://www.pharmexeceurope.com/europharmexec/Europe-the-new-economic-threat/ArticleStandard/Article/detail/520558?ref=25 Pharm Exec Europe's new columnist Arkhipov looks at how the balance of pharma power has shifted in the last few years. 2008-06-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/232008/520558null HTML http://www.pharmexeceurope.com/europharmexec/Sales-training-for-REAL-behaviour-change/ArticleStandard/Article/detail/520564?ref=25 New Pharm Exec Europe supplement explores how sales reps' thinking and behaviour can really be changed. 2008-06-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/232008/520564null HTML http://www.pharmexeceurope.com/europharmexec/News/Favrille-staring-bankruptcy-in-the-face/ArticleStandard/Article/detail/520561?ref=25 SpecifId failure puts pressure on other cancer vaccines, according to EP Vantage. 2008-06-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/232008/520561null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/23-May-08-Pfizer-wins-green-accolade/ArticleStandard/Article/detail/518811?ref=25 Pfizer has been named one of the top 50 environmentally friendly companies in the UK by the Sunday Times. 2008-05-23T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/212008/518811null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/23-May-08-Chantix-side-effects-pose-risk-to-rare-P/ArticleStandard/Article/detail/518818?ref=25 Having been touted as one of Pfizer's few pipeline success stories in recent years, sales expectations for smoking cessation drug Chantix look set to be reined in following a number of high profile side-effect warnings. 2008-05-23T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/212008/518818null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Supply+Chain%2C+Technology/23-May-08-New-software-combines-BlackBerry-and-Dig/ArticleStandard/Article/detail/518812?ref=25 PaperIQ have launched a new software package which will make it easier for users in the pharmaceutical sector to combine the benefits of BlackBerry smartphones and Digital Pen and paper (DPP). 2008-05-23T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/212008/518812null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/20-May-08-Antisoma-to-buy-Xanthus/ArticleStandard/Article/detail/518097?ref=25 Antisoma, the British biotechnology company, is to buy the US cancer specialist, Xanthus Pharmaceuticals for £26.8 million in shares. 2008-05-20T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/212008/518097null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/20-May-08-Archimedes-licenses-chitosan-drug-delive/ArticleStandard/Article/detail/518098?ref=25 Archimedes Development and Ploughsgare Innovations have announced the licensing by Archimedes of a portfolio of patents relating to the use of chitosan for drug delivery. 2008-05-20T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/212008/518098null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/20-May-08-Chiltern-looks-towards-Latin-America/ArticleStandard/Article/detail/518099?ref=25 Chiltern, the UK based contract research organisation (CRO), has appointed a new general manager for the Latin America region and plans to open an office in Argentina during the third quarter of this year. 2008-05-20T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/212008/518099null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/19-May-08-First-bird-flu-vaccine-approved-in-Europ/ArticleStandard/Article/detail/517682?ref=25 GlaxoSmithKline (GSK) has received European approval for its H5N1 pre-pandemic vaccine, Prepandrix. 2008-05-19T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/212008/517682null HTML http://www.pharmexeceurope.com/europharmexec/Recruitment%3A+R%26D/16-May-08-Pfizer-names-new-Senior-VP-of-its-Oncolo/ArticleStandard/Article/detail/517386?ref=25 Garry A. Nicholson has been named as Pfizer's new Senior Vice President and General Manager of the company?s newly formed Oncology Business Unit. 2008-05-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517386null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Sales+%26+Marketing/16-MAY-08-Oncology-drug-sales-will-grow-faster-tha/ArticleStandard/Article/detail/517350?ref=25 According to IMS Health, sales of cancer drugs will grow at nearly double the rate of the global pharmaceutical market and could reach $80 billion by 2012. 2008-05-16T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517350null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Supply+Chain%2C+Technology/15-May-08-Black-market-medicines-are-an-increasing/ArticleStandard/Article/detail/517156?ref=25 The European Federation of Pharmaceutical Industries and Associations (EFPIA) has said that the industry needs to do more to prevent the increase in counterfeit medicine sales. 2008-05-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517156null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/15-May-08-Pfizer-may-be-looking-to-buy-MediGene/ArticleStandard/Article/detail/517160?ref=25 The word on the grapevine is that Pfizer is looking to take over the German Biotech company, MediGene. 2008-05-15T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/517160null HTML http://www.pharmexeceurope.com/europharmexec/Reflector/Does-your-company-qualify-for-EMEA-support/ArticleStandard/Article/detail/516833?ref=25 Smaller firms developing advanced therapy medicines will be entitled to expert assistance from the European Medicines Agency as from the end of this year, reports Reflector. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516833null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Corporate+Strategy/Is-your-company-operating-at-peak-efficiency/ArticleStandard/Article/detail/516836?ref=25 If not, running a virtual plant and 'simulating the future' can help you get there. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516836null HTML http://www.pharmexeceurope.com/europharmexec/Learn-about-Condition-Branding/ArticleStandard/Article/detail/516835?ref=25 Join the IMS workshop dedicated to a groundbreaking new approach to marketing. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516835null HTML http://www.pharmexeceurope.com/europharmexec/Articles%3A+Sales+%26+Marketing/The-10-Biggest-Mistakes-Sales-People-Make/ArticleStandard/Article/detail/516834?ref=25 To help answer the question 'What makes a sales person successful?' we have to ask 'What are the biggest mistakes a sales person makes?' Avoid those and you might find yourself doing rather well, says Lars Tewes. 2008-05-14T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516834null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Regulatory%2C+Legal/13-May-08-Oral-Hycamtin-approved-in-Europe-for-sma/ArticleStandard/Article/detail/516456?ref=25 GlaxoSmithKline (GSK) has received approval from the European Commission for oral Hycamtin (topotecan hard capsules) as a treatment for relapsed small cell lung cancer. 2008-05-13T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516456null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/13-May-08-Merck-enters-into-development-deal-with-/ArticleStandard/Article/detail/516455?ref=25 Merck & Co has entered into a strategic product development deal with Ranbaxy, India's largest pharmaceutical company. 2008-05-13T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516455null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/12-May-08-EUSA-acquires-Cytogen/ArticleStandard/Article/detail/516140?ref=25 EUSA Pharma has completed its acquisition of Cytogen Corporation, following approval by Cytogen's shareholders. 2008-05-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516140null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Finance%2C+M%26A/12-May-08-Sanofi-Aventis-shares-fall/ArticleStandard/Article/detail/516141?ref=25 Shares in Sanofi-Aventis have gone down by 4.3% following the announcement by a Swiss generics company that it is close to getting approval for its version of the anti-platelet agent, Plavix. 2008-05-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516141null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Sales+%26+Marketing/12-May-08-Symbicort-patent-revoked/ArticleStandard/Article/detail/516142?ref=25 AstraZeneca has been told that its patents for Symbicort (formoterol/budesonide), as a treatment for chronic obstructive pulmonary disease (COPD), are no longer valid in Europe. 2008-05-12T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/202008/516142null HTML http://www.pharmexeceurope.com/europharmexec/News/08-May-08-GSK-acquire-Sitris-Pharmaceuticals/ArticleStandard/Article/detail/515450?ref=25 GlaxoSmithKline (GSK) has taken over Sitris Pharmaceuticlas as part of an agreement involving the acquisition of the company's research portfolio. 2008-05-08T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/515450null HTML http://www.pharmexeceurope.com/europharmexec/News/08-May-08-New-HIV-drug-receives-marketing-authoris/ArticleStandard/Article/detail/515451?ref=25 Boehringer Ingelheim has been granted full marketing authorisation by the European Commission for its HIV protease inhibitor (PI), Aptivus (tipranavir). 2008-05-08T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/515451null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+R%26D/06-May-08-Pfizer-to-open-biotech-plant-in-Ireland/ArticleStandard/Article/detail/514784?ref=25 Pfizer is to invest 190 million euros in a new biotech plant in Ireland for the production of experimental medicines. 2008-05-06T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/514784null HTML http://www.pharmexeceurope.com/europharmexec/News/06-May-08-Application-for-Iressa-to-be-sold-in-Eur/ArticleStandard/Article/detail/514785?ref=25 AstraZeneca has applied to sell its lung cancer drug Iressa in Europe as a treatment for selected patients. 2008-05-06T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/192008/514785null HTML http://www.pharmexeceurope.com/europharmexec/News/02-May-08-Court-of-Appeal-rules-against-NICE/ArticleStandard/Article/detail/514046?ref=25 The Court of Appeal in England has ruled that the National Institute for Health and Clinical Excellence (NICE) was insufficiently transparent when disclosing why it had decided to limit access to Alzheimer's drugs. 2008-05-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/514046null HTML http://www.pharmexeceurope.com/europharmexec/News/02-May-08-IMI-up-and-running-in-Europe/ArticleStandard/Article/detail/514045?ref=25 A partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations, called Innovative Medicines Initiative (IMI), is now up and running. 2008-05-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/514045null HTML http://www.pharmexeceurope.com/europharmexec/News%3A+Corporate+Strategy/02-May-08-New-Corporate-Executive-Team-for-GSK/ArticleStandard/Article/detail/514044?ref=25 GlaxoSmithKline has announced a number of changes to its Corporate Executive Management team which will take effect when Andrew Witty assumes the role of Chief Executive Officer on May 22nd. 2008-05-02T04:00:00Z http://www.pharmexeceurope.com/europharmexec/data/articlestandard/europharmexec/182008/514044null HTML